Itoco (ITMC) Other Financing: $0.57 Mil (TTM As of Sep. 2010)


What is Itoco Other Financing?

Itoco ITMC Other Financing is $0.57 Mil as of Sep. 2010.

Itoco's Other Financing for the three months ended in Sep. 2010 was $0.00 Mil.

Itoco's Other Financing for the trailing twelve months (TTM) ended in Sep. 2010 was $0.57 Mil.

Itoco Other Financing Historical Data

* Premium members only.

The historical data trend for Itoco's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Itoco Other Financing Chart

Itoco Annual Data
Trend Dec08 Dec09
Other Financing
1.52 -0.04

Itoco Quarterly Data
Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.57 0.00 0.00 0.00

Itoco Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.57 Mil mean?
Itoco (ITMC) has a Other Financing of $0.57 Mil as of Sep. 2010. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Itoco and its competitors.
Is Itoco's Other Financing too high?
Itoco's current Other Financing is $0.57 Mil.
How does Itoco's Other Financing compare to BLAIF?
Itoco's Other Financing of $0.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Itoco and its competitors. Itoco's current Other Financing is $0.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Itoco stock overvalued right now?
Itoco (ITMC) has a current Other Financing of $0.57 Mil. The current Other Financing is $0.57 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Itoco (ITMC), the current Other Financing is $0.57 Mil as of Sep. 2010. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Itoco Business Description

Address 50 West Liberty Street, Suite 880, Reno, NV, USA, 89501
Itoco Inc is focused on developing and bringing biotech products to the market via co-development and joint venture arrangements with various companies. The company is currently examining various technologies that seek to control and/or identify bio-contaminants such as viruses and bacteria.